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Abstract 
Purpose: To investigate the exact role of the proviral integration site for Moloney murine leukemia 
virus-1 (PIM-1) on autophagy as well as the underlying molecular mechanisms in melanoma. 
Methods: mRNA expression levels in A375 and G361 human melanoma cell lines were measured 
using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Enzyme-linked 
immunosorbent (ELISA) and western blotting assays were applied to determine protein expression 
levels, while cell viability was evaluated using Cell Counting Kit 8 and colony formation assay. Flow 
cytometric analysis and caspase 3/7 activity assay were used to assess apoptosis. 
Results: The results show that pharmacological inhibition of PIM-1 with its potent inhibitor (SMI-4a) 
suppressed cell viability and induced apoptosis in melanoma cell lines A375 and G361. SMI-4a also 
induced autophagy through inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of 
rapamycin (mTOR) axis in melanoma cells. Furthermore, chloroquine, an inhibitor of autophagy, 
potentiated the SMI-4a-induced inhibition of tumour growth and promotion of apoptosis in melanoma 
cells in vitro and in vivo.  
Conclusions: These results suggest that SMI-4a induces protective autophagy via PI3K/AKT/mTOR 
signaling pathway in melanoma cells. Thus, a combination of SMI-4a and an inhibitor of autophagy 
might be a novel approach to melanoma therapy.  
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Melanoma, arising from epidermal melanocytes, 
is a highly aggressive skin cancer type with 
mounting substantial incidence in the past 30 
years [1]. It is associated with early metastasis, 
poor prognosis, very low 5-year survival rate, and 
high mortality. Therefore, it is imperative to 
explore the mechanism of melanoma 
pathogenesis, identify novel therapeutic targets, 
and develop effective strategies for melanoma 
treatment. 
 
PIM-1, which belongs to the PIM family, is 
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overexpressed in numerous solid tumours [2]. A 
growing body of evidence has demonstrated that 
atopic expression of PIM-1 in cancer cells is 
responsible for tumour growth and metastasis 
[3]. Inhibition of PIM-1 by knockdown studies can 
reduce proliferation and viability in preclinical 
models of melanoma [4]. However, the exact role 
of PIM-1 as a therapeutic target in melanoma is 
not clearly understood. 
 
Autophagy is widely implicated in various 
biological activities such as programmed cell 
death, differentiation, innate and adaptive 
immunity, aging, tumourigenesis, and tumour 
progression [5]. Autophagy plays dual and 
contradictory roles in cancer. Recent findings 
showed that pharmacotherapy induced cell 
autophagy, which in turn promoted the survival of 
tumour cells [6]. Inhibition of autophagy 
potentiated arginase-induced cytotoxicity in 
breast cancer cells [7]. Therefore, it is critical and 
necessary to investigate the functions of 
autophagy in certain contexts. 
 
To better understand the biological function of 
PIM-1 in melanoma and to determine the 
therapeutic application of PIM-1 inhibitors in 
melanoma, we investigated whether 
pharmacological inhibition of PIM-1 could induce 
autophagy in melanoma, and explored the 






Human melanoma cell lines A375 and G361 
were purchased from the Cell Bank of the 
Chinese Academy of Sciences (Shanghai, 
China). The cells were cultured in Dulbecco's 
Modified Eagle Medium supplemented with 10 % 
FBS, 100 units/mL penicillin, and 100 µg/mL 
streptomycin (Gibco BRL, Grand Island, NY). 
The cells were grown at 37 °C in a humidified 
atmosphere with 5% CO2. 
 
Cell viability assay 
 
Cell survival was evaluated with Cell Counting Kit 
8 (CCK8, Beyotime, Shanghai, China), according 
to the manufacturer’s instructions, and the colony 
formation assay. For the CCK8 assay, cells (3 × 
103 cells/ well) were seeded into 96-well plates 
and then treated with SMI-4a, with double 
dilution from 10 μM (Sigma-Aldrich, Merck 
KGaA, Darmstadt, Germany). The viability of the 
cells was analyzed after incubation for 24, 48, 
and 72 h, respectively. The optical density values 
were read at 450 nm using a microplate reader 
(Thermo, USA). For the colony formation assay, 
600 cells were seeded into six-well plates and 
treated with SMI-4a (0.3 and 1 μM) at 37 °C for 
10 days, followed by fixation and staining with 
0.5 % crystal violet and methanol. The mean 
value of three independent experiments were 
calculated. 
 
Flow cytometry  
 
For the detection of apoptosis, A375 and G361 
cells were treated with SMI-4a (1 μM) in 
complete medium for 48 h. Cells were collected, 
resuspended in binding buffer, and stained with 
annexin-V-FITC/PI apoptosis detection kit (KGI 
Biotech, Nanjing, China) according to the 
manufacturer’s protocol The stained cells were 
resuspended for flow cytometry analysis. 
(FACSCalibur, BD Biosciences, San Jose, 
California, USA). For the detection of autophagic 
body production, A375 and G361 cells were 
treated with SMI-4a (3, 1, and 0.3 μM) for 48 h. 
Cells were collected and stained with acridine 
orange (1 μg/mL) and protected from light for 15 
min at room temperature. The stained cells were 
resuspended for flow cytometry analysis. 
 
Caspase 3/7 activity assay 
 
Cells were plated into 96-well plates and treated 
with SMI-4a (1 μM) and/or CQ (3 μM) for 48 h. 
CQ is a lysosome inhibitor which blocks the 
fusion of autophagosomes and lysosomes [8]. 
Caspase-Glo® 3/7 Reagent was added to the 
wells, and luminescence was recorded using the 
Caspase-Glo® 3/7 Assay kit (Promega 
Corporation, Madison, WI, USA). The data were 
calculated at a wavelength of 499 nm with a 
microplate reader. Values from wells containing 
culture medium alone served as background. 
 
Protein isolation and western blot analysis 
 
Total protein was extracted from cells using RIPA 
Buffer (Cell Signaling Technology, Danvers, MA, 
USA). The protein concentration was assessed 
with a bicinchoninic acid (BCA) assay kit from 
EMD Millipore (Billerica, MA, USA). Protein was 
separated with SDS polyacrylamide gel 
electrophoresis, and electrophoretically 
transferred onto PVDF membranes. The primary 
antibodies used were as following: LC3B 
antibody (Cell Signaling Technology, 1:1000, no. 
3868), Beclin-1 antibody (Cell Signaling 
Technology, 1:1000, no. 3495), Atg5 antibody 
(Cell Signaling Technology, 1:1000, no. 9980), 
AKT antibody (Cell Signaling Technology, 
1:1000, no. 4685), p-AKT antibody (Cell 
Signaling Technology, 1:1000, no. 4060), mTOR 
antibody (Cell Signaling Technology, 1:1000, no. 
Chen et al 
403 
 
2983), p-mTOR antibody (Cell Signaling 
Technology, 1:1000, no. 5536),) and GAPDH 
antibody (Beyotime, 1:5000, no. AG019). Bands 
were developed using the RapidStep™ ECL 
Reagent (EMD Millipore) according to the 
manufacturer’s directions. 
 
Tumour xenografts  
 
A375 cells (3×106) were subcutaneously 
inoculated into the right flank of five six-week old 
nude mice (Charles River Laboratories). 
Measurement of tumor length and width was 
performed every three days with calipers, and 
tumour volume was calculated using the formula: 
volume = ½ × length × width. The study was 
approved by Animal Ethic Committee of Scientific 
research IRB of Wannan Medical College 
Yijishan Hospital (approval ref no. 2016-13). All 
experimental procedures involving animals were 
performed according to the Principles of 
Laboratory Animal Care (NIH publication no. 85-
23, revised 1985) and/or the Declaration of 





All the data are presented as mean ± standard 
deviation (SD, n = 3). Statistical analysis was 
performed with SPSS 13.0 software (SPSS, Inc., 
Chicago, IL, USA). The Student t test or ANOVA 
were used to analyze differences between the 
different treatment groups. P value below 0.05 




PIM-1 specific inhibitor, SMI-4a, suppressed 
cell viability in melanoma cells 
 
To confirm whether the pharmacological 
inhibition of PIM-1 with SMI-4a had a similar 
effect on cell survival, human melanoma cells 
A375 and G361 were treated with SMI-4a. CCK8 
cytotoxicity assays indicated that SMI-4a showed 
significant inhibitory effect on cell viability in a 
time- and dose-dependent manner in A375 and 
G361 melanoma cells (Figure 1A). The anti-
proliferative effect of SMI-4a was also examined 
using the colony formation assay. Consistent 
with the cell viability results, treatment with SMI-
4a remarkably inhibited cell colony formation 
ability in a dose-dependent fashion in A375 and 
G361 cells (p < 0.001, Figure 1B). These results 
demonstrate that SMI-4a inhibits cell viability in 




Figure 1: PIM-1 specific inhibitor, SMI-4a, suppresses 
melanoma cell viability. (A) SMI-4a suppress 
melanoma cell viability. A375 cells and G361 cells 
were incubated with a concentration gradient of SMI-
4a for 24, 48, and 72 h. For a negative control, 0.1% 
DMSO was used. (B) SMI-4a reduced clonogenic 
survival in melanoma cells. Cells were treated with 
SMI-4a (1 and 0.3 μM) for 10 days. Treatment with 
0.1% DMSO served as the control. Colonies were 
fixed, stained with crystal violet and quantified; *p < 
0.05 and ***p < 0.001, when compared with the 
negative control. Data are expressed as mean ± SD 
 
Inhibition of PIM-1 with SMI-4a promotes 
apoptosis in melanoma cells 
 
Next, we further investigated whether SMI-4a 
exerted an effect on cell apoptosis. We found 
that SMI-4a-treated A375 cells displayed greater 
numbers of early apoptotic cells as well as late 
apoptotic/secondary necrotic cells relative to the 
control group (23.4 vs. 4.46; p < 0.001; Figure 2 
A). A similar effect of SMI-4a on apoptosis was 
observed in G361 cells (22.0 vs. 2.91; p < 0.001 
Figure 2A). An increase in apoptosis was further 
evidenced by the detection of upregulated 
caspase 3/7 activity, relative to the control group, 
in A375 cells (157 vs. 46; p < 0.001; Figure 2 B) 
and G361 cells (188 vs. 32; p < 0.001; Figure 2 
B). These results demonstrate that SMI-4a 
induced apoptosis in A375 and G361 melanoma 
cells in vitro. 
 
SMI-4a induced autophagy via PI3K/AKT/ 
mTOR signaling pathway 
 
To investigate the effects of SMI-4a on 
autophagy, autophagic body production was 
assessed with acridine orange staining. It was 
found that SMI-4a treatment significantly 
increased autophagic body production in a dose-
dependent manner relative to that of the control 
group, in A375 cells and G361 cells (p < 0.01, 
Figure 3 A). Moreover, several critical 
determinants of autophagy include Atg5, LC3, 
and Beclin-1 were examined. Our results showed 
that SMI-4a resulted in an increase in the protein 
levels of LC3-II, Atg5, and Beclin1 in a dose-
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dependent manner in A375 and G361 (Figure 3 
B). SMI-4a induces the autophagy of melanoma 
cells. To further investigate the molecular 
mechanisms underlying SMI-4a triggered 
autophagy, changes in PI3K/AKT/mTOR 
signaling upon treatment of SMI-4a were 
assessed using western blot analysis. 
Interestingly, SMI-4a treatment caused a 
reduction in the phosphorylation levels of Akt and 
mTOR, but showed no effect on total ATK and 




Figure 2: The PIM-1-specific inhibitor SMI-4a 
promotes apoptosis. (A) SMI-4a promoted the early 
proportion of apoptotic and late apoptotic/secondary 
necrotic phenotype in A375 cells and G361 cells. Cells 
were treated with 1 μM SMI-4a for 48 h, and apoptosis 
was measured by PI-FACS analysis. DMEM 10 % 
FBS with 0.1 % DMSO was used as negative control. 
(D) SMI-4a induced caspase 3/7 activity. Cells were 
treated with 1 μM SMI-4a for 48 h, and caspase 3/7 
activity was measured; ***p < 0.001, when compared 
with negative control. Data are expressed as the mean 
± SD 
 
Blocking autophagy enhanced the anti-
tumour effect of SMI-4a in vitro 
 
To verify the effect of autophagy on the SMI-4a-
induced inhibition of cell viability and increase of 
apoptosis, an inhibitor of autophagy, chloroquine 
(CQ), was used to suppress autophagy in human 
melanoma cells. As shown in Figure 4A, the 
combination of SMI-4a with CQ exerted a greater 
inhibitory effect on cell survival, relative to that of 
each individual agent (p < 0.001, Figure 4 A). 
Consistent with this, western blotting showed that 
CQ enhanced the SMI-4a-induced expression 
levels of LC3B-II and Beclin-1, indicating that CQ 
inhibited autophagy in SMI-4a-treated cells 
(Figure 4 B). Furthermore, inhibition of 
autophagy with CQ also enhanced SMI-4a-
induced caspase3/7 activity in melanoma cells (p 




Figure 3: The PIM-1-specific inhibitor SMI-4a induces 
autophagy. (A) SMI-4a-induced autophagic body 
production. A375 and G361 cells were treated with 
SMI-4a (3, 1, and 0.3 μM) for 48 h. The level of 
autophagic body production was measured using flow 
cytometry analysis. (B) A375 and G361 cells were 
incubated with different concentrations of SMI-4a (3, 1 
and 0.3 μM) for 24 h. The protein expression levels of 
LC3B, Atg5, and Beclin1 were evaluated with western 
blot. (C) A375 and G361 cells were treated with 
different concentrations of SMI-4a at (10, 3, and 1 μM) 
for 24 h. The protein expression of P-AKT, total AKT, 
P-mTOR. and total mTOR were measured by western 
blot. **p < 0.01 and ***p < 0.001, when compared with 
the negative control. Data are expressed as mean ± 
SD 
 
Inhibition of autophagy potentiated SMI-4a-
induced growth inhibition of melanoma cells 
in vivo 
 
Given that SMI-4a and chloroquine showed a 
combinatorial effect on inhibition of cell survival 
and induction of apoptosis in vitro, we 
investigated whether SMI-4a and chloroquine 
showed this combinatorial effect in vivo. As 
expected, SMI-4a treatment significantly inhibited 
tumour growth compared to treatment with 
vehicle alone (p < 0.001), whereas chloroquine 
was not active. The combination of SMI-4a and 
chloroquine was more efficacious than each 
individual agent (p < 0.01, Figure 5). 
 





Figure 4: Inhibition of autophagy potentiated SMI-4a-
induced growth inhibition and apoptosis. (A) Cell 
viability was evaluated with the CCK8 assay in 
melanoma cells that were treated with 1 μM SMI-4a in 
the absence or presence of 3 μM chloroquine for 48 h. 
(B) Western blotting was used to analyse the protein 
levels of LC3B and Beclin-1. (C) Caspase 3/7 activity 
was analysed in melanoma cells treated with 1 μM 
SMI-4a in the absence or presence of 3 μM 
chloroquine for 48 h; **p < 0.01 and ***p < 0.001, 
when compared with the negative control. Data are 





Figure 5: Inhibition of autophagy enhanced the anti-
tumour effect of SMI-4a in a melanoma xenograft 
model. Melanoma A375 cells were implanted in the 
right flank to induce tumour growth, as described in 
the Methods. When the tumour volume was 150–200 
mm3, the mice were randomly grouped into four 
groups of 6 mice each. Mice in the four groups were 
given orally administrations of 0.5 % MC (vehicle 
control), SMI-4a (15 mg/kg, po, qid), chloroquine (30 
mg/kg, po, qid), or SMI-4a plus chloroquine, 
respectively. The tumour volume in each mouse was 
measured using calipers every 3 days, and average 
tumour volume for each group was calculated. : 




Melanoma is an aggressive type of skin cancer. 
It is common in adults and has multiple 
underlying pathogenic mechanisms. Despite 
progress in the treatment of melanoma, the 
prognosis of patients has remained dismal [11]. 
Therefore, it is critical to identify the underlying 
molecular mechanisms in order to support the 
development of effective and novel treatments. 
PIM1 is overexpressed in several tumour types, 
including solid tumours and liquid malignancies, 
and contributes to tumour growth and metastasis 
[12]. Expression of PIM1 is associated with 
tumour aggressiveness, and it is a marker of 
poor prognosis in various tumours [13]. Drugs 
targeting PIM kinases are under clinical 
development to determine their potential in 
patients with hematologic malignancies or solid 
tumours. Therefore, PIM-1 kinase may be a 
potential target for cancer treatment. 
 
According to data from the Cancer Genome Atlas 
(TCGA), it has been shown that alterations in the 
PIM-1 gene, including mutations, amplifications, 
and deletions, account for up to 8% of 
melanomas. An inhibitory effect of PIM-1 
silencing on the proliferation of melanoma cells 
has been previously suggested [3]. SMI-4a is a 
small molecular highly selective PIM-1 inhibitor 
that has been found to block PIM-1 kinase 
activity in vitro and in vivo [14]. In this study, we 
demonstrated that blockade of PIM-1 with SMI-
4a results in a remarkable decrease in cell 
viability, and data from the colony formation 
assay was consistent with this observation. 
Evidence from the annexin V-PI assay and 
caspase 3/7 activity analysis in melanoma cells. 
An evidence indicated that SMI-4a could promote 
apoptosis in vitro. The complex interplay 
between PI3K/AKT/mTOR axis and the 
autophagic process is well documented [15-17]. 
The PI3K/Akt/mTOR signaling pathway 
negatively regulates autophagy through 
phosphorylation of Akt, downstream effector 
mTOR, and its substrate p70S6K [18]. It was 
further revealed that the PI3K/AKT/mTOR 
signaling pathway was involved in SMI-4a 
triggered autophagy in melanoma cells. 
 
Increasing evidence has indicated that treatment 
can induce autophagy in various tumour types. 
However, the contradictory roles of autophagy in 
cancer can be a double-edged sword, and are 
often puzzling. Some drugs induce autophagic 
cell death, whereas autophagy induced by other 
drugs appears to function as a protective cell 
survival mechanism [19,20]. It has been reported 
that autophagy was responsible for drug 
resistance in certain contexts [21]. For instance, 
chemotherapeutic agents induced autophagy as 
a possible survival mechanism [22]. This study 
reports for the first time that blockade of PIM-1 
with SMI-4a significantly increased autophagic 
body production and increased several critical 
determinants of autophagy, including Atg5, LC3, 
and Beclin-1, in a dose-dependent manner. To 
further to examine the contributions of autophagy 
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induced by SMI-4a treatment, the autophagy 
inhibitor CQ was used to pharmacologically 
inhibit SMI-4a-induced autophagy. CQ functions 
to block lysosomal acidification and 
autophagosome degradation [23]. Our findings 
indicate that inhibition of autophagy with CQ 
could remarkably potentiate SMI-4a-induced anti-
tumour activity in vitro and in vivo, indicating the 
cytoprotective role of autophagy in SMI-4a 




The findings of this study indicate that inhibition 
of PIM-1 with SMI-4a treatment suppresses cell 
survival, promote apoptosis in melanoma cells, 
and induce autophagy. Importantly, inhibition of 
autophagy enhances the potency of SMI-4a in 
vitro and in vivo, suggesting a cytoprotective role 
for SMI-4a-induced autophagy. Moreover, PI3K 
research indicates that SMI-4a in combination 
with an autophagy inhibitor might be a novel 
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